Clinical Comparative Study to Evaluate the Efficacy and Safety of Recombinant Anti-TNF-alpha Antibodies for Injection

NCT04178850 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

568

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL: GB242
BIOLOGICAL: Infliximab

Sponsor

Genor Biopharma Co., Ltd.